BIIB
Price
$196.58
Change
-$2.09 (-1.05%)
Updated
Jun 18 closing price
Capitalization
29.02B
24 days until earnings call
Intraday BUY SELL Signals
PACB
Price
$1.40
Change
+$0.06 (+4.48%)
Updated
Jun 18 closing price
Capitalization
434.84M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BIIB vs PACB

BIIB vs PACB Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), IQVIA Holdings (NYSE:IQV), Moderna (NASDAQ:MRNA), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7.81B. The market cap for tickers in the group ranges from 658 to 182.21B. AMGN holds the highest valuation in this group at 182.21B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 4%. For the same Theme, the average monthly price growth was 21%, and the average quarterly price growth was 6,388%. CRVO experienced the highest price growth at 74%, while CODX experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was 106%. For the same stocks of the Theme, the average monthly volume growth was 76% and the average quarterly volume growth was 10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 69
Price Growth Rating: 52
SMR Rating: 85
Profit Risk Rating: 88
Seasonality Score: 25 (-100 ... +100)

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB).

Market Cap

The average market capitalization across the group is 14.73B. The market cap for tickers in the group ranges from 434.84M to 29.02B. BIIB holds the highest valuation in this group at 29.02B. The lowest valued company is PACB at 434.84M.

High and low price notable news

The average weekly price growth across all stocks in the group was 1%. For the same group, the average monthly price growth was 12%, and the average quarterly price growth was -6%. PACB experienced the highest price growth at 4%, while BIIB experienced the biggest fall at -2%.

Volume

The average weekly volume growth across all stocks in the group was 37%. For the same stocks of the group, the average monthly volume growth was 24% and the average quarterly volume growth was -70%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 90
P/E Growth Rating: 43
Price Growth Rating: 36
SMR Rating: 89
Profit Risk Rating: 100
Seasonality Score: 0 (-100 ... +100)
VS
BIIB vs. PACB commentary
Jun 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and PACB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 22, 2026
Stock price -- (BIIB: $196.58 vs. PACB: $1.40)
Brand notoriety: BIIB: Notable vs. PACB: Not notable
BIIB represents the Pharmaceuticals: Major, while PACB is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: BIIB: 153% vs. PACB: 70%
Market capitalization -- BIIB: $29.02B vs. PACB: $434.84M
BIIB [@Pharmaceuticals: Major] is valued at $29.02B. PACB’s [@Medical/Nursing Services] market capitalization is $434.84M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $979.64B to $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $153.99B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $179.82B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 2 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • BIIB’s FA Score: 2 green, 3 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, BIIB is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 2 TA indicator(s) are bullish while PACB’s TA Score has 2 bullish TA indicator(s).

  • BIIB’s TA Score: 2 bullish, 5 bearish.
  • PACB’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than PACB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -1.69% price change this week, while PACB (@Medical/Nursing Services) price change was +3.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +23.45%. For the same industry, the average monthly price growth was +12.35%, and the average quarterly price growth was -13.81%.

Reported Earning Dates

BIIB is expected to report earnings on Jul 16, 2026.

PACB is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.18% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Medical/Nursing Services (+23.45% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIIB($29B) has a higher market cap than PACB($435M). BIIB YTD gains are higher at: 11.700 vs. PACB (-25.134). BIIB has higher annual earnings (EBITDA): 2.7B vs. PACB (-103.11M). BIIB has more cash in the bank: 4.28B vs. PACB (276M). PACB has less debt than BIIB: PACB (703M) vs BIIB (6.56B). BIIB has higher revenues than PACB: BIIB (9.94B) vs PACB (160M).
BIIBPACBBIIB / PACB
Capitalization29B435M6,667%
EBITDA2.7B-103.11M-2,618%
Gain YTD11.700-25.134-47%
P/E Ratio21.14N/A-
Revenue9.94B160M6,211%
Total Cash4.28B276M1,552%
Total Debt6.56B703M933%
FUNDAMENTALS RATINGS
BIIB vs PACB: Fundamental Ratings
BIIB
PACB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
79100
PRICE GROWTH RATING
1..100
2449
P/E GROWTH RATING
1..100
1472
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIIB's Valuation (80) in the Biotechnology industry is in the same range as PACB (100). This means that BIIB’s stock grew similarly to PACB’s over the last 12 months.

BIIB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PACB (100). This means that BIIB’s stock grew similarly to PACB’s over the last 12 months.

BIIB's SMR Rating (79) in the Biotechnology industry is in the same range as PACB (100). This means that BIIB’s stock grew similarly to PACB’s over the last 12 months.

BIIB's Price Growth Rating (24) in the Biotechnology industry is in the same range as PACB (49). This means that BIIB’s stock grew similarly to PACB’s over the last 12 months.

BIIB's P/E Growth Rating (14) in the Biotechnology industry is somewhat better than the same rating for PACB (72). This means that BIIB’s stock grew somewhat faster than PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBPACB
RSI
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
68%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
57%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
73%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
59%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
57%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
71%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signal:
Gain/Loss:
PACB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSCNX24.080.35
+1.47%
Loomis Sayles Small Cap Value N
RGLEX31.260.44
+1.43%
American Funds Global Insight R-4
IRLIX48.090.52
+1.09%
Voya Russell Large Cap Index Port A
AFDGX51.440.51
+1.00%
American Century Large Cap Equity R5
SBHSX15.56-0.02
-0.13%
Segall Bryant & Hamill Intl Sm Cp Ret

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-1.05%
AMGN - BIIB
51%
Loosely correlated
-1.19%
PFE - BIIB
51%
Loosely correlated
-2.74%
AZN - BIIB
49%
Loosely correlated
-1.66%
MRK - BIIB
46%
Loosely correlated
-1.36%
BMY - BIIB
41%
Loosely correlated
-2.32%
More

PACB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with QSI. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then QSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
+4.48%
QSI - PACB
53%
Loosely correlated
+5.79%
BFLY - PACB
50%
Loosely correlated
+55.87%
ILMN - PACB
48%
Loosely correlated
+1.79%
AZTA - PACB
45%
Loosely correlated
+2.80%
TWST - PACB
42%
Loosely correlated
+5.66%
More